Guangyu An

机构：Shaanxi University of Science and Technology · ORCID：0000-0003-1597-5188

发表论文 124 篇 · 总被引 2735 次 · h-index 31

代表论文

• Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study (2024 · Journal for ImmunoTherapy of Cancer · 被引 27)
• GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration (2024 · Cancer Immunology Immunotherapy · 被引 13)
• DCLK1 Drives EGFR-TKI-Acquired Resistance in Lung Adenocarcinoma by Remodeling the Epithelial–Mesenchymal Transition Status (2023 · Biomedicines · 被引 10)
• Efficacy and safety of glecirasib (JAB-21822) monotherapy and in combination with cetuximab in patients with KRAS G12C-mutated advanced colorectal cancer. (2025 · Journal of Clinical Oncology · 被引 9)
• First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial (2025 · The Lancet Respiratory Medicine · 被引 7)
• Construction of a novel immune response prediction signature to predict the efficacy of immune checkpoint inhibitors in clear cell renal cell carcinoma patients (2023 · Heliyon · 被引 3)